By Iain Gilbert
Date: Tuesday 27 Feb 2018
(ShareCast News) - Cambridge-based biopharmaceutical firm GW Pharmaceuticals has been granted orphan drug designation for its proprietary cannabinoid product platform for the treatment of tuberous sclerosis (TS) from the European Medicines Agency.
By Oliver Haill
Date: Monday 26 Sep 2016
(ShareCast News) - GW Pharmaceuticals said it planned to apply to market its cannabis-derived treatment for childhood-onset epilepsy early next year after the drug produced strong results from its late-stage clinical trail.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 0.00 |
| Closing Price Change | $ 0.00 |
| % Change | 0.00 % |
| 52 Week High | $0.00 |
| 52 Week Low | $0.00 |
| Volume | 0 |
| Shares Issued | 25.37m |
| RiskGrade | 464 |
| Time | Volume / Share Price |
| 0 @ $0.00 |
You are here: research